Trial · NCT00818883
Adverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 36
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood creatinine increased | Investigations | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 38 | 302 | |
| other | Blood creatinine increased | Investigations | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 27 | 303 | |
| other | Dizziness | Nervous system disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 37 | 302 | |
| other | Dizziness | Nervous system disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 32 | 303 | |
| other | Headache | Nervous system disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 16 | 302 | |
| other | Headache | Nervous system disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 16 | 303 | |
| serious | Angina unstable | Cardiac disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 1 | 302 | |
| serious | Angina unstable | Cardiac disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 0 | 303 | |
| serious | Coronary artery occlusion | Cardiac disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 1 | 302 | |
| serious | Coronary artery occlusion | Cardiac disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 0 | 303 | |
| serious | Coronary artery stenosis | Cardiac disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 1 | 302 | |
| serious | Coronary artery stenosis | Cardiac disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 0 | 303 | |
| serious | Gastrointestinal haemorrhage | Gastrointestinal disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 1 | 302 | |
| serious | Gastrointestinal haemorrhage | Gastrointestinal disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 0 | 303 | |
| serious | Sudden death | General disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 1 | 302 | |
| serious | Sudden death | General disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 1 | 303 | |
| serious | Chest discomfort | General disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 1 | 302 | |
| serious | Chest discomfort | General disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 0 | 303 | |
| serious | Chest pain | General disorders | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 0 | 302 | |
| serious | Chest pain | General disorders | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 1 | 303 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00818883/events